Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
Patients with COPD prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils? Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020
Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
Sputum eosinophil counts in a large population of mild-to-moderate asthmatics: distribution, relationship with methacholine bronchial responsiveness and influence of a regular treatment with low doses of inhaled corticosteroids Source: Eur Respir J 2001; 18: Suppl. 33, 531s Year: 2001
Stability of blood eosinophils over time in patients with asthma Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021
Association between blood eosinophil count and risk of exacerbations in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017
Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD? Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population Source: ERJ Open Res, 8 (1) 00606-2021; 10.1183/23120541.00606-2021 Year: 2022
Blood eosinophil count and exacerbation risk in patients with COPD Source: Eur Respir J, 50 (1) 1700761; 10.1183/13993003.00761-2017 Year: 2017
Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019
Blood eosinophilia in patients with COPD, a real life evaluation Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS) Year: 2018
Correlation between sputum and blood eosinophils in asthmatic and COPD patients with comorbidities. Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018
Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018
Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018
Characterisation of UK and US COPD populations in reference to exacerbation frequency and blood eosinophils level Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018